It is with much excitement and enthusiasm to announce that two new members join our Omixon family to further contribute our commercial operations both in the Americas and Europe. Richard Pallin will join Omixon Management as VP Commercial Operations, while Joe Yearsley will join Omixon’s US Operations as Sales Director, Americas.

Richard comes from the City of Sunderland, on the North-East coast of the UK, near Newcastle. He has two sons, Andrew and Daniel, and 2 rescued Staffordshire bull terrier dogs, Max and Izzy.
Before coming into the molecular diagnostics field, he was a merchant navy engineer, travelling around the world on a ship carrying iron ore, but finally decided to go into further education in the sciences and then a BSc in Applied Biology. He started his scientific commercial career as a FAS/Engineer with Chiron Diagnostics supporting customers and distributors using the b-DNA viral load monitoring system throughout EMEA.

Richard has over 20 years of commercial experience in the molecular diagnostics and research markets of EMEA and the US. Gaining experience in positions within support, sales as well as marketing. Having worked for large companies including Roche Diagnostics and Bayer, then moving into smaller companies with innovative and disruptive technologies like Luminex, GenMark or Singulex, he has a broad range of experience that will definitely bring value to Omixon. He has led EU and global product launches with replacement or disruptive technology products and systems.

He enjoys the challenges within smaller organisations, that are commercializing novel and innovative new technology products to positively impact on patient care.

Outside of work, Richard will often be found in remote areas of Scotland, driving, walking, and exploring the interesting and historical sites. He also enjoys photography and using a camera drone to explore the remote countryside and views.

“I am truly looking forward to being a part of an established market leader in the field of HLA, making a positive contribution to the companies growth and contribute to improve patients outcome” – said Richard.

Joe has been in sales for over 20 years for a number of life science companies – Diasorin, Merck, Life Technologies, Thermo Fisher and most recently Qiagen. Importantly, he has also worked in Transplantation/HLA with Linkage Biosciences, where he was the first dedicated in-market person brought in to develop that market from scratch between 2014 and 2016.

Joe is excited to contribute his sales expertise, enthusiasm and experience to Omixon’s team of NGS & HLA experts, in particular as we build towards ASHI, the launch of OmniType in Q4 and the post-transplant Chimerism product that is currently still in the business development phase.  His passion is working for young companies / new divisions and making them common place names in the industry.

Welcome to the team Richard and Joe, wishing you good luck!